Regulators and industry stakeholders are reassessing whether body weight alone is a sufficient endpoint for obesity therapies. In a recent Boehringer Ingelheim discussion, Brian Hilberdink highlighted a shift toward metabolic health as a more meaningful indicator of clinical benefit. The
